medigraphic.com

2002, Number S1

<< Back Next >>

Arch Cardiol Mex 2002; 72 (S1)

Progresses in treatment of diabetic patients with ischemic cardiopathy

Gaxiola-López E, Eng-Ceceña L

Language: Spanish
References: 15
Page: 69-75
PDF size: 74.79 Kb.


ABSTRACT

Among the risk factors for ischemic cardiopathy none influences more long-term restenosis and mortality as diabetes mellitus. Diabetes mellitus is ranked third as cause of death; 65 to 85% of these patients die due to cardiovascular disease. The use of coronary stents associated to glycoprotein IIb/IIIa inhibitors has proven to be superior to stents alone or PTCA in the treatment of ischemic cardiopathy in diabetic patients. Despite these improved results, restenosis rates remain higher as compared to non-diabetic patients. Intracoronary radiation has been shown decrease restenosis and repeat target lesion revascularizations in diabetic patients with intra-stent restenosis. In order to decrease restenosis in diabetic patients, stents coated with site-specific pharmacological and molecular approaches may prove useful in suppressing hyperplasia of the intimal and preventing restenosis. Coronary artery bypass grafting seems to be the best option for diabetic patients with multiple coronary artery disease, especially if they have proximal left anterior descending artery estenosis, complex lesions to be approached by angioplasty, previous myocardial infarction, three vessel disease, or impaired left ventricular function. In spite of improvements in the treatment of diabetic patients with coronary artery disease, restenosis and mortality rates continue to be higher as compared to non-diabetic patients; therefore, new strategies are required.


REFERENCES

  1. Moreno P, Murcia AM, Palacios IF, et al: Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 2000; 102: 2180-2184.

  2. Vinik AI, Erbas T, Park TS, et al: Platelet dysfunction in type 2 diabetes. Diabetes Care 2001; 24: 1476-1485.

  3. Gaxiola E, Vlietstra RE, Brenner AS, et al: Diabetes and multiple stents independently double the risk of short-term revascularization. J Interven Cardiol 2000; 13: 87-91.

  4. Kornowsky R, Mintz GS, Kent KM, et al: Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study. Circulation 1997; 95: 1366-1369.

  5. Lincoff AM, Califf RM, Moliterno DJ, et al: Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. N Engl J Med 1999; 341: 319-27.

  6. Stone GW, Mehran R, Dangas G, et al: Differential impact on survival of electrocardiographic Q-wave versus enzymatic myocardial infarction after percutaneous intervention: a device-specific analysis of 7147 patients. Circulation 2001; 104: 642-47.

  7. Topol EJ, Moliterno DJ, Herrmann HC, et al: Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344: 1888-94.

  8. Moliterno DJ, Herrmann HC, Powers ER, et al: The effects of tirofiban versus abciximab among diabetic patients undergoing stent placement: The TARGET trial. J Am Coll Cardiol 2001; 37: 9A.

  9. The BARI Investigators. Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. J Am Coll Cardiol 2000; 35: 1122-29.

  10. Serruys PW, Unger F, Souza JE, et al: Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001; 344: 1117-24.

  11. Rodríguez A, Bernardi V, Navia J et al. Argentine randomized study: coronary angioplasty with stenting vs coronary bypass surgery in patients with multiple-vessel disease (ERACI II): 30-day and one-year follow-up results. J Am Coll Cardiol 2001; 37: 51-58.

  12. Ousman Y, Sharma M: The irrefutable importance of glycemic control. Clinical Diabetes 2001; 19: 71-71.

  13. Marso SP, Ellis SG, Tuzcu EM, et al. The importance of proteinuria as a determinant of death following percutaneous coronary revascularization in diabetics. J Am Coll Cardiol 1999; 33: 1269-77.

  14. León MB, Teirstein PS, Moses JW, et al: Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med 2001; 344: 250-56.

  15. Kleiman NS, Califf RM: Results from late-breaking clinical trials sessions at ACCIS 2000 and ACC 2000. JACC 2000; 36: 310-25.




2020     |     www.medigraphic.com